Literature DB >> 24739829

What regulates hepcidin in poly-transfused β-Thalassemia Major: erythroid drive or store drive?

Richa Chauhan1, Sunita Sharma, Jagdish Chandra.   

Abstract

BACKGROUND: Hepcidin, a key regulator of iron homeostasis, is increased by iron overload and inflammation while suppressed by hypoxia. In spite of iron overload in β-Thalassemia Major (β-TM), a paradoxical decrease in hepcidin is observed. AIM: To assess the opposing effects of enhanced erythropoiesis due to anemia and iron overloading on hepcidin in β-TM patients. SETTING AND
DESIGN: This prospective observational study was done at our tertiary care hospital.
MATERIALS AND METHODS: Eighty-three pediatric polytransfused (> 20 transfusions) patients of β-TM were compared with 70 children who served as controls. Serum assays for ferritin, transferrin receptors (sTfR) and hepcidin were performed. STATISTICAL ANALYSIS: Independent Student t test was used to compare variables between both the groups. A Pearson correlation coefficient was used to find any correlation between ferritin, sTfR and hepcidin.
RESULTS: The mean value of hepcidin in β-TM children was 13.88±10.68 ng/ml (range, 0.9-60 ng/ml) and showed significant negative correlation with sTfR (r = -0.296, P < 0.0066). However, there was no correlation of hepcidin with ferritin. Ferritin and sTfR were significantly elevated in β-TM children compared to controls (P < 0.001). The mean serum hepcidin/ferritin index in the study group (0.00552) was significantly lower (P value < 0.001) than the controls (0.378) thus indicating inappropriate levels of hepcidin to iron overload.
CONCLUSION: In polytransfused β-TM children increased iron demand dominates over iron overload in regulating hepcidin. In spite of excessive iron load, the inappropriate hepcidin levels may further contribute to iron overload enhancing iron toxicity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24739829     DOI: 10.4103/0377-4929.130891

Source DB:  PubMed          Journal:  Indian J Pathol Microbiol        ISSN: 0377-4929            Impact factor:   0.740


  6 in total

1.  Serum Hepcidin as a Diagnostic Marker of Severe Iron Overload in Beta-thalassemia Major.

Authors:  Ahmed Maher Kaddah; Amina Abdel-Salam; Marwa Salah Farhan; Reham Ragab
Journal:  Indian J Pediatr       Date:  2017-06-10       Impact factor: 1.967

2.  The Frequency of Adrenal Insufficiency in Adolescents and Young Adults with Thalassemia Major versus Thalassemia Intermedia in Iran.

Authors:  Sara Matin; Masoud Ghanei Jahromi; Zohreh Karemizadeh; Sezaneh Haghpanah; Vincenzo De Sanctis; Ashraf Soliman; Javad Dehbozorgian; Zahra Majd; Narges Rezaei; Mehran Karimi
Journal:  Mediterr J Hematol Infect Dis       Date:  2015-01-01       Impact factor: 2.576

3.  Green tea activity and iron overload induced molecular fibrogenesis of rat liver.

Authors:  Gadah I Al-Basher
Journal:  Saudi J Biol Sci       Date:  2017-08-18       Impact factor: 4.219

4.  Iron Status in Newly Diagnosed β-Thalassemia Major: High Rate of Iron Status due to Erythropoiesis Drive.

Authors:  Susi Susanah; Lulu Eva Rakhmilla; Mohammad Ghozali; Jessica Oktavianus Trisaputra; Octawyana Moestopo; Yunia Sribudiani; Ponpon S Idjradinata; Ani Melani Maskoen
Journal:  Biomed Res Int       Date:  2021-04-16       Impact factor: 3.411

5.  The Relation between Serum Hepcidin, Ferritin, Hepcidin: Ferritin Ratio, Hydroxyurea and Splenectomy in Children with β-Thalassemia.

Authors:  Nagwa Abdallah Ismail; Sonia Adolf Habib; Ahmed A Talaat; Naglaa Omar Mostafa; Eman A Elghoroury
Journal:  Open Access Maced J Med Sci       Date:  2019-08-14

6.  Correlation of hepcidin and serum ferritin levels in thalassemia patients at Chiang Mai University Hospital.

Authors:  Adisak Tantiworawit; Sujaree Khemakapasiddhi; Thanawat Rattanathammethee; Sasinee Hantrakool; Chatree Chai-Adisaksopha; Ekarat Rattarittamrong; Lalita Norasetthada; Pimlak Charoenkwan; Somdet Srichairatanakool; Kanda Fanhchaksai
Journal:  Biosci Rep       Date:  2021-02-26       Impact factor: 3.840

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.